Analysis Presented at ASCO GU Highlights Significant Differences in Clinical Treatment Plans and Expert Recommendations for Patients With Advanced RCC

Share Article

Clinical Care Options’ data presented at 2018 Genitourinary Cancers Symposium suggest HCPs' planned treatment approach for advanced RCC patients often differs from expert recommendations

Given that expert recommendations often changed the treatment plan of HCPs, the potential of an online tool to improve clinical outcomes in patients with advanced RCC warrants further investigation. - Won Kim, MD

Health care professionals (HCPs) often select disparate treatment approaches compared with expert recommendations, according to an analysis of data captured with an online tool developed by Clinical Care Options (CCO) in collaboration with 5 renal cell carcinoma (RCC) experts. Detailed analysis of the data was presented by Won Kim, MD, at the 2018 Genitourinary Cancers Symposium in San Francisco, California.

The treatment landscape for advanced RCC is complex and rapidly evolving, making it difficult for many HCPs, particularly those in community settings, to make informed treatment decisions for their patients. CCO collaborated with 5 RCC experts—Thomas E. Hutson, DO, PharmD, FACP; Won Kim, MD; Robert Motzer, MD; Elizabeth R. Plimack, MD, MS; and Brian Rini, MD, FACP—to develop an online tool that provides patient-specific guidance on treatment decisions for advanced RCC. More than 70% of participants indicated that the recommendations provided by the tool either changed or confirmed their management plan.

“The data [from this tool] are very interesting, especially the differences between expert recommendations and the community physicians using the tool, as well as the treatment trends of both experts and HCPs over time,” said author Brian Rini, MD, FACP, Professor of Medicine and Leader of the GU Program at Cleveland Clinic Taussig Cancer Institute.

Lead author Won Kim, MD, Assistant Clinical Professor of Medicine and Urology at the University of California, San Francisco, said, “Given that expert recommendations often changed the treatment plan of HCPs, the potential of an online tool to improve clinical outcomes in patients with advanced RCC warrants further investigation.”

CCO and the experienced RCC experts from leading academic institutions will continue to provide updated treatment recommendations for patients with advanced RCC to improve patient care and overall outcomes. Additional iterations of this treatment support tool are planned. The most recent version of CCO’s RCC tools, with treatment perspectives from an international panel of experts, can be found at http://www.clinicaloptions.com/RCCGlobalTool

Kim W, Rosenthal KM, Hutson TE, Motzer R, Plimack ER, Obholz KL, Vinther A, Rini B. Analysis of an Online Tool to Explore Evolving Practice Patterns in Renal Cell Carcinoma (RCC). Program and abstracts of the 2018 Genitourinary Cancers Symposium. February 8-10, 2018.

About Clinical Care Options
Clinical Care Options, LLC, is a global leader in the development of innovative educational programs and technology platforms. CCO’s team has been a pioneer in the creation of continuing education and decision support resources for healthcare professionals both in the United States and around the world for more than 2 decades. For more information, visit clinicaloptions.com.

Contact:
Tradd Sanderson | Director of Marketing
Clinical Care Options
Telephone: 855.224.2241
Email: tsanderson@clinicaloptions.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Carlton Sanderson

Tradd Sanderson
Visit website